If dyspnea worsens or occurs consistently, a LABA or LAMA is indicated
Product is not specified sku: item } Product Overview Benefits Supplement Facts Practitioner Resources Clinical Applications Downloads Program Details Product Overview Benefits Supplement Facts Practitioner Resources Clinical Applications Downloads Program Details
At minimum: Outcomes Weight trend (weekly average) Waist circumference Body composition if available (DEXA, BIA with consistency) Strength markers (basic lifts, grip strength, functional tests) Safety Blood pressure + resting HR A1c and fasting glucose (more often if diabetes) CMP (liver/kidney) Lipids (periodic) If manipulating GH/IGF-1 signaling: IGF-1 (and clinical context matters) Stop criteria Persistent tachycardia, edema, severe fatigue, worsening glycemia, abnormal labs, or new symptoms you cant explain The what to ask your clinic questions (high signal, low fluff) If a clinic recommends a peptide stack, ask: What is the problem were solving, in one sentence
14(6):813 Lousa I, Reis F, Beiro I, Alves R, Belo L, Santos-Silva A (2021) New potential biomarkers for chronic kidney disease management a review of the literature
Laboratory studies have highlighted possible roles in apoptosis regulation, insulin signaling, proteasome activity, and neurodegenerative disease models